Siri Amundsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Siri Amundsen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hedvig Nordeng
PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
3 shared publications Anne Christine Poole
Volvat Medical Centre, Oslo, Norway
2 shared publicationsElisabet Nordmo
Regional Medicines Information and Pharmacovigilance Centre (RELIS) University Hospital of North Norway Tromsø Norway
2 shared publications- Georg Sager
Department of Medical Biology, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, Norway
2 shared publications - Olav Spigset
Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway
2 shared publications - Ole-Martin Fuskevåg
Department of Laboratory Medicine, Division of Diagnostic Services, University Hospital of North Norway, Tromsø, Norway
2 shared publications
Latest Publications
- Open Access
- 17 March 2021
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 128 (6) , 795-804
Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding
Clinical data on the transfer of triptans into human breast milk remain scarce. In a lactation study including 19 breastfeeding women with migraine, we examined the excretion of six different triptans into milk. Following intake of a single dose, each participant collected seven breast milk samples at predefined intervals up to 24 hours after dose. Triptan concentrations in milk were measured using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). Infant drug exposure was estimated by calculating the relative infant dose (RID). Twenty‐two breast milk sample sets were obtained for sumatriptan (n = 8), rizatriptan (n = 5), zolmitriptan (n = 4), eletriptan (n = 3), almotriptan (n = 1) and naratriptan (n = 1). Based on the average concentration in milk throughout the day, estimated mean RIDs (with range in parenthesis) were as follows: eletriptan 0.6% (0.3%‐0.8%), sumatriptan 0.7% (0.2%‐1.8%), rizatriptan 0.9% (0.3%‐1.4%), almotriptan 1.8% (‐), zolmitriptan 2.1% (0.7%‐5.3%) and naratriptan 5.0% (‐). Infant drug exposure through breastfeeding appears to be low and indicates that use of the triptans in this study is compatible with breastfeeding. Naratriptan may not be first choice in breastfeeding mothers initiating triptans during the neonatal period.
- 17 March 2021
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 128 (6) , 795-804
Open AccessTransfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding
Clinical data on the transfer of triptans into human breast milk remain scarce. In a lactation study including 19 breastfeeding women with migraine, we examined the excretion of six different triptans into milk. Following intake of a single dose, each participant collected seven breast milk samples at predefined intervals up to 24 hours after dose. Triptan concentrations in milk were measured using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). Infant drug exposure was estimated by calculating the relative infant dose (RID). Twenty‐two breast milk sample sets were obtained for sumatriptan (n = 8), rizatriptan (n = 5), zolmitriptan (n = 4), eletriptan (n = 3), almotriptan (n = 1) and naratriptan (n = 1). Based on the average concentration in milk throughout the day, estimated mean RIDs (with range in parenthesis) were as follows: eletriptan 0.6% (0.3%‐0.8%), sumatriptan 0.7% (0.2%‐1.8%), rizatriptan 0.9% (0.3%‐1.4%), almotriptan 1.8% (‐), zolmitriptan 2.1% (0.7%‐5.3%) and naratriptan 5.0% (‐). Infant drug exposure through breastfeeding appears to be low and indicates that use of the triptans in this study is compatible with breastfeeding. Naratriptan may not be first choice in breastfeeding mothers initiating triptans during the neonatal period.
- Open Access
- 1 September 2019
- Published by Elsevier in Reproductive Toxicology
- Vol. 88, 141
#25 Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding
- 1 September 2019
- Published by Elsevier in Reproductive Toxicology
- Vol. 88, 141
Open Access#25 Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding
- Open Access
Risk perception, beliefs about medicines and medical adherence among pregnant and breastfeeding women with migraine: findings from a cross-sectional study in Norway
Objectives To examine risk perception, beliefs about migraine medications and medical adherence among pregnant and breastfeeding women with migraine. Design and setting Cross-sectional study conducted in Norway from October 2013 to February 2014. Data were collected via an anonymous, electronic questionnaire. Participants Women with migraine, either pregnant or having delivered within the previous 18 months. Main outcomes Women’s perception of teratogenic risk (numeric rating scale 0–10) was obtained for 14 different drugs/substances, including medications commonly used in the acute treatment of migraine. Women’s perspectives on migraine drug therapy were assessed by 10 statements from the Beliefs about Medicines Questionnaire (BMQ-Specific) and six pregnancy/breastfeeding-specific statements. Adherence to migraine treatment during pregnancy and breastfeeding period was assessed by maternal self-report. Results The study population included 401 women with migraine, of which 140 were pregnant and 261 were new mothers. More than 70% of the women reported use of migraine medications during pregnancy. Still, the majority severely overestimated the risk associated with migraine medications and were concerned about using medications to manage their migraine during pregnancy and breastfeeding. Almost 9 out of 10 women had at some point deliberately avoided using migraine medications during their pregnancy. Women reporting use of migraine medications, however, were more positive and overestimated to a lesser extent the risks of using such medications in pregnancy compared with their counterparts. Conclusions Women with migraine severely overestimated the risk associated with migraine pharmacotherapy in pregnancy. The majority of women were concerned about use of migraine medications during pregnancy and breastfeeding and reported non-adherence to needed treatment. More attention should be focused on women’s beliefs and concerns regarding migraine pharmacotherapy during pregnancy and breastfeeding in order to improve management of disease, reduce unfounded concerns and enhance adherence to needed treatment.
Open AccessRisk perception, beliefs about medicines and medical adherence among pregnant and breastfeeding women with migraine: findings from a cross-sectional study in Norway
Objectives To examine risk perception, beliefs about migraine medications and medical adherence among pregnant and breastfeeding women with migraine. Design and setting Cross-sectional study conducted in Norway from October 2013 to February 2014. Data were collected via an anonymous, electronic questionnaire. Participants Women with migraine, either pregnant or having delivered within the previous 18 months. Main outcomes Women’s perception of teratogenic risk (numeric rating scale 0–10) was obtained for 14 different drugs/substances, including medications commonly used in the acute treatment of migraine. Women’s perspectives on migraine drug therapy were assessed by 10 statements from the Beliefs about Medicines Questionnaire (BMQ-Specific) and six pregnancy/breastfeeding-specific statements. Adherence to migraine treatment during pregnancy and breastfeeding period was assessed by maternal self-report. Results The study population included 401 women with migraine, of which 140 were pregnant and 261 were new mothers. More than 70% of the women reported use of migraine medications during pregnancy. Still, the majority severely overestimated the risk associated with migraine medications and were concerned about using medications to manage their migraine during pregnancy and breastfeeding. Almost 9 out of 10 women had at some point deliberately avoided using migraine medications during their pregnancy. Women reporting use of migraine medications, however, were more positive and overestimated to a lesser extent the risks of using such medications in pregnancy compared with their counterparts. Conclusions Women with migraine severely overestimated the risk associated with migraine pharmacotherapy in pregnancy. The majority of women were concerned about use of migraine medications during pregnancy and breastfeeding and reported non-adherence to needed treatment. More attention should be focused on women’s beliefs and concerns regarding migraine pharmacotherapy during pregnancy and breastfeeding in order to improve management of disease, reduce unfounded concerns and enhance adherence to needed treatment.
- 13 September 2016
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 72 (12) , 1525-1535
Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women
Purpose Migraine is highly prevalent among women of fertile age. The main objectives of this study were to describe the prevalence and patterns of use of antimigraine medications during pregnancy and breastfeeding and to identify maternal and migraine-related factors associated with medication use during pregnancy. Methods The study is a cross-sectional internet-based survey among pregnant women and new mothers with migraine conducted in Norway from October 1, 2013 to February 1, 2014. Descriptive statistics were used to explore patterns of medication use, and logistic regression analysis was performed to examine the association between maternal socio-demographic and migraine-related factors and use of antimigraine medications during pregnancy. Results Of the total 401 respondents, 34.9 % were pregnant and 65.1 % had delivered within the last 18 months. The majority reported use of antimigraine medications during pregnancy (73.3 %) and postpartum (64.8 %), yet less than a third considered their migraine to be optimally treated during pregnancy (31.7 %) and the breastfeeding period (27.2 %). The patterns of medication use markedly changed during pregnancy and postpartum. Women with moderate or severe migraine were more likely to use antimigraine medications during pregnancy compared to women with mild migraine. Conclusions Despite the fact that antimigraine medications were commonly used, the majority of the women felt that their migraine was suboptimally treated during pregnancy and postpartum. There was a decline in the use of medicines in pregnancy and postpartum, and the patterns of use markedly changed. Efforts to improve treatment of women with migraine during pregnancy and breastfeeding should be undertaken.
- 13 September 2016
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 72 (12) , 1525-1535
Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women
Purpose Migraine is highly prevalent among women of fertile age. The main objectives of this study were to describe the prevalence and patterns of use of antimigraine medications during pregnancy and breastfeeding and to identify maternal and migraine-related factors associated with medication use during pregnancy. Methods The study is a cross-sectional internet-based survey among pregnant women and new mothers with migraine conducted in Norway from October 1, 2013 to February 1, 2014. Descriptive statistics were used to explore patterns of medication use, and logistic regression analysis was performed to examine the association between maternal socio-demographic and migraine-related factors and use of antimigraine medications during pregnancy. Results Of the total 401 respondents, 34.9 % were pregnant and 65.1 % had delivered within the last 18 months. The majority reported use of antimigraine medications during pregnancy (73.3 %) and postpartum (64.8 %), yet less than a third considered their migraine to be optimally treated during pregnancy (31.7 %) and the breastfeeding period (27.2 %). The patterns of medication use markedly changed during pregnancy and postpartum. Women with moderate or severe migraine were more likely to use antimigraine medications during pregnancy compared to women with mild migraine. Conclusions Despite the fact that antimigraine medications were commonly used, the majority of the women felt that their migraine was suboptimally treated during pregnancy and postpartum. There was a decline in the use of medicines in pregnancy and postpartum, and the patterns of use markedly changed. Efforts to improve treatment of women with migraine during pregnancy and breastfeeding should be undertaken.